MX2019003821A - Composiciones de aminoacidos y usos de las mismas. - Google Patents
Composiciones de aminoacidos y usos de las mismas.Info
- Publication number
- MX2019003821A MX2019003821A MX2019003821A MX2019003821A MX2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A MX 2019003821 A MX2019003821 A MX 2019003821A
- Authority
- MX
- Mexico
- Prior art keywords
- vivo
- treating
- differentiation
- present disclosure
- proliferation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 title 1
- 210000000130 stem cell Anatomy 0.000 abstract 7
- 208000027418 Wounds and injury Diseases 0.000 abstract 2
- 230000006378 damage Effects 0.000 abstract 2
- 230000004069 differentiation Effects 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 208000014674 injury Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000004682 mucosal barrier function Effects 0.000 abstract 2
- 230000035755 proliferation Effects 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000004210 Pressure Ulcer Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000024245 cell differentiation Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 230000007850 degeneration Effects 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 238000011476 stem cell transplantation Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación proporciona composiciones y métodos para promover la proliferación y/o diferenciación de células madre y/o progenitoras. Las composiciones proporcionadas pueden ser útiles en el tratamiento de una enfermedad o afecciones relacionadas con la función de barrera de la mucosa, por ejemplo, la cicatrización de heridas, el tratamiento de afecciones de la piel (por ejemplo, dermatitis atópica, psoriasis, úlceras de decúbito o afecciones relacionadas con el envejecimiento de la piel), el tratamiento de trastomos pulmonares (por ejemplo, asma), una afección relacionada con la mejora de la función de barrera mucosa, y/o el tratamiento de lesiones de la mucosa gastrointestinal en un sujeto que lo necesite. La presente divulgación también proporciona métodos para promover la proliferación y/o diferenciación de células madre y/o las células progenitoras en un sujeto que necesita tal tratamiento mediante la administración de una composición. La capacidad de estimular la proliferación y/o diferenciación de las células madre y/o las células progenitoras in vivo, ex vivo y/o in vitro proporciona un gran beneficio. La presente divulgación puede ser utilizada para aumentar las poblaciones de células madre in vivo, ex vivo y/o in vitro. El trasplante de células madre proporciona tratamientos y/o curas de muchos estados de enfermedad, degeneración y/o lesión.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403965P | 2016-10-04 | 2016-10-04 | |
| US201662421443P | 2016-11-14 | 2016-11-14 | |
| PCT/US2017/055167 WO2018067717A1 (en) | 2016-10-04 | 2017-10-04 | Amino acid compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003821A true MX2019003821A (es) | 2019-12-18 |
Family
ID=61831937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003821A MX2019003821A (es) | 2016-10-04 | 2017-10-04 | Composiciones de aminoacidos y usos de las mismas. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11576884B2 (es) |
| EP (1) | EP3522882A4 (es) |
| JP (2) | JP7267546B2 (es) |
| CN (2) | CN110062621B (es) |
| AU (1) | AU2017338887B2 (es) |
| BR (1) | BR112019006742A2 (es) |
| CA (2) | CA3135553C (es) |
| MX (1) | MX2019003821A (es) |
| WO (1) | WO2018067717A1 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102069790B1 (ko) | 2010-09-24 | 2020-01-23 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| EP2968241B1 (en) | 2013-03-11 | 2018-10-31 | University of Florida Research Foundation, Inc. | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| US20230255916A1 (en) * | 2016-10-04 | 2023-08-17 | University Of Florida Research Foundation, Inc. | Amino acid compositions and uses thereof |
| BR112020020318A2 (pt) * | 2018-04-04 | 2021-01-05 | University Of Florida Research Foundation, Incorporated | Composições para tratamento de pele |
| US20210212973A1 (en) * | 2018-07-30 | 2021-07-15 | Almeda Labs Llc | Cardioprotective amino acid formulation |
| RU2709502C1 (ru) * | 2019-09-23 | 2019-12-18 | Виктор Александрович Сисев | Фармацевтическая композиция для парентерального капельного введения |
| EP4084784A4 (en) * | 2020-01-13 | 2024-01-17 | Monash University | Compositions and methods |
| JP7470376B2 (ja) * | 2020-03-31 | 2024-04-18 | 国立大学法人山口大学 | 顎下腺の萎縮抑制剤及び創傷治癒促進剤 |
| IL299488A (en) | 2020-07-02 | 2023-02-01 | Univ Florida | Preparations for promoting hydration and methods of using them |
| CN114097952A (zh) * | 2020-08-28 | 2022-03-01 | 河北科星药业有限公司 | 毛丝鼠专用的营养添加剂、其制备方法及应用 |
| AU2022424131A1 (en) | 2022-01-03 | 2024-07-25 | Amilyfe, Llc | Formulations and methods for skin care |
| US11878073B1 (en) | 2022-09-20 | 2024-01-23 | Entrinsic, LLC | Generation of hydration-targeted formulations and methods of use therein |
| CN117085142A (zh) * | 2023-08-04 | 2023-11-21 | 中山大学附属第七医院(深圳) | 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用 |
| CN117159520A (zh) * | 2023-08-17 | 2023-12-05 | 中国人民解放军海军军医大学第一附属医院 | 竹红菌甲素在制备抑制胰腺纤维化的药物中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6130394A (en) | 1991-03-05 | 1994-08-15 | Miris Medical Corporation | Apparatus for providing a timed release of an amount of aerosol medication |
| EP0940154B1 (en) | 1991-07-02 | 2007-04-18 | Nektar Therapeutics | Device for delivering aerosolized medicaments |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5558085A (en) | 1993-01-29 | 1996-09-24 | Aradigm Corporation | Intrapulmonary delivery of peptide drugs |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
| BR9607336A (pt) | 1995-02-23 | 1997-11-25 | Novartis Nutrition Ag | Composições de aminoácidos e utilidades das mesmas em nutrição clinica |
| US5976574A (en) | 1996-12-31 | 1999-11-02 | Inhale Therapeutic Systems | Processes for spray drying hydrophobic drugs in organic solvent suspensions |
| AU776679B2 (en) | 1998-11-13 | 2004-09-16 | Children's Hospital Of Los Angeles | Methods of facilitating vascular growth |
| GB0009056D0 (en) | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| CA2557814A1 (en) * | 2004-03-01 | 2005-09-15 | Lumen Therapeutics, Llc | Compositions and methods for treating diseases |
| US20070010459A1 (en) | 2005-01-14 | 2007-01-11 | Ying Liu | Application of asiatic acid and its derivatives to treat pulmonary fibrosis |
| EP1864692A1 (en) | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| MX2010000172A (es) * | 2006-08-04 | 2012-09-25 | Shs Int Ltd | Formula libre de proteina. |
| CN101815441A (zh) | 2007-08-03 | 2010-08-25 | 安敏诺技术公司 | 氨基酸和肽产品 |
| JP5576097B2 (ja) * | 2009-11-17 | 2014-08-20 | 大塚製薬株式会社 | 気道抵抗改善剤 |
| IT1396935B1 (it) | 2009-11-26 | 2012-12-20 | Solartium Entpr Ltd | Uso di una combinazione per il trattamento delle mucositi indotte da radiazioni o da chemioterapici |
| IT1397023B1 (it) * | 2009-11-27 | 2012-12-20 | Professional Dietetics Srl | Composizioni comprendenti amminoacidi, per il trattamento della broncopneumopatia cronica ostruttiva |
| MX2012008017A (es) * | 2010-01-08 | 2012-10-03 | Harvard College | Métodos y composiciones para tratar biopelículas. |
| KR102069790B1 (ko) | 2010-09-24 | 2020-01-23 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 위장 기능을 증진시키기 위한 물질 및 방법 |
| JP2012214451A (ja) * | 2011-03-25 | 2012-11-08 | En Otsuka Pharmaceutical Co Ltd | 炎症性疾患用アミノ酸組成物 |
| EP2793813A1 (en) * | 2011-12-21 | 2014-10-29 | Motolese, Pasquale | Cosmetic composition and uses thereof in the treatment of lipodystrophies |
| KR20140120941A (ko) | 2012-02-08 | 2014-10-14 | 유니버시티 오브 플로리다 리서치 파운데이션, 인크. | 설사를 치료하기 위한 물질 및 방법 |
| EP2968241B1 (en) * | 2013-03-11 | 2018-10-31 | University of Florida Research Foundation, Inc. | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| DE102013224993A1 (de) * | 2013-12-05 | 2015-06-11 | Henkel Ag & Co. Kgaa | Haarbehandlungsmittel mit substituierten Silikon(en) |
| US10413528B2 (en) * | 2014-10-20 | 2019-09-17 | John H. Plumb | Methods to inhibit infection during wound healing with topical compositions including amino acids |
| EP3223809A4 (en) * | 2014-11-24 | 2018-08-15 | Entrinsic Health Solutions, Inc. | Amino acid compositions for the treatment of symptoms of disease |
-
2017
- 2017-10-04 CA CA3135553A patent/CA3135553C/en active Active
- 2017-10-04 US US16/339,461 patent/US11576884B2/en active Active
- 2017-10-04 WO PCT/US2017/055167 patent/WO2018067717A1/en not_active Ceased
- 2017-10-04 BR BR112019006742A patent/BR112019006742A2/pt not_active Application Discontinuation
- 2017-10-04 AU AU2017338887A patent/AU2017338887B2/en active Active
- 2017-10-04 EP EP17859127.7A patent/EP3522882A4/en active Pending
- 2017-10-04 JP JP2019539737A patent/JP7267546B2/ja active Active
- 2017-10-04 CA CA3039514A patent/CA3039514C/en active Active
- 2017-10-04 MX MX2019003821A patent/MX2019003821A/es unknown
- 2017-10-04 CN CN201780074351.9A patent/CN110062621B/zh active Active
- 2017-10-04 CN CN202211258479.XA patent/CN115645388B/zh active Active
-
2023
- 2023-04-04 JP JP2023060554A patent/JP7593577B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017338887A1 (en) | 2019-05-02 |
| CA3039514C (en) | 2022-01-25 |
| CA3135553C (en) | 2024-05-21 |
| JP2023100617A (ja) | 2023-07-19 |
| JP7593577B2 (ja) | 2024-12-03 |
| US11576884B2 (en) | 2023-02-14 |
| CN110062621B (zh) | 2022-11-01 |
| CN115645388B (zh) | 2024-12-10 |
| JP2019530750A (ja) | 2019-10-24 |
| US20210283081A1 (en) | 2021-09-16 |
| EP3522882A1 (en) | 2019-08-14 |
| CN110062621A (zh) | 2019-07-26 |
| CN115645388A (zh) | 2023-01-31 |
| JP7267546B2 (ja) | 2023-05-02 |
| EP3522882A4 (en) | 2020-06-24 |
| BR112019006742A2 (pt) | 2019-09-03 |
| WO2018067717A1 (en) | 2018-04-12 |
| CA3135553A1 (en) | 2018-04-12 |
| AU2017338887B2 (en) | 2020-09-03 |
| CA3039514A1 (en) | 2018-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003821A (es) | Composiciones de aminoacidos y usos de las mismas. | |
| Rangatchew et al. | Mesenchymal stem cell therapy of acute thermal burns: a systematic review of the effect on inflammation and wound healing | |
| WO2012065027A3 (en) | Compositions, kits and methods for treatment of cardiovascular, immunological, and inflammatory diseases | |
| AR081450A1 (es) | Tratamiento de sarcoidosis usando celulas madre de placenta | |
| WO2015118537A3 (en) | Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions | |
| FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| MY194587A (en) | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration | |
| TN2013000427A1 (en) | Modified acid alpha glucosidase with accelerated processing | |
| EP4124346A3 (en) | Compositions and methods for treating diseases | |
| MX2020012018A (es) | Composiciones para el tratamiento de condiciones de la piel. | |
| WO2010097788A3 (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| Melotti et al. | Could cold plasma act synergistically with allogeneic mesenchymal stem cells to improve wound skin regeneration in a large size animal model? | |
| RU2014150505A (ru) | Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды | |
| DK2714888T3 (da) | Rekombinant gær | |
| ES2571991T3 (es) | Procedimientos para tratar y/o revertir enfermedades y/o trastornos neurodegenerativos | |
| MX2021002017A (es) | Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion. | |
| MX359686B (es) | Formulaciones de nanoparticulas de polionasol líquidas y en gel. | |
| BR112022012917A2 (pt) | Composição tópica, kit, métodos para tratar ou melhorar um distúrbio da pele, de mucosa, de cavidade corporal, método para tratar uma condição relacionada a jak, método para tratar ou prevenir um distúrbio dermatológico, e, uso da composição tópica | |
| MX2009004962A (es) | Metodo para tratar asma, rinitis alergia y trastornos de la piel. | |
| WO2010108488A3 (de) | Pflanzen-extrakte zur behandlung von hauterkrankungen | |
| WO2011139246A9 (en) | Topical or injectable composition comprising humic acid salts and polyvinylpyrrolidone for the treatment of skin diseases | |
| Xiao et al. | Comparative study on the efficacy of intracoronary infusion with various types of autologous bone marrow stem cells for patients with dilated cardiomyopathy | |
| CN106902011A (zh) | 一种中药消炎祛痘面膜 | |
| CN105521015A (zh) | 一种治疗脚气的中药配方 |